soul trial oral semaglutide cardiovascular outcomes 2024 results nejm Oral Semaglutide's Impact on Cardiovascular Events in Type 2 Diabetes Patients with Cardiovascular and Kidney Disease: SOUL Trial Michael Albert, MD on X:

821 Gomez-Perez, A

In addition, a selective GIP agonist showed very low effectiveness in reducing weight, while this co-agonist showed synergism in reducing fat mass in obese rodents

Key takeaways Retatrutide isn't approved yet and isn't expected to launch in the UK until at least mid-2026 In clinical trials, target doses ranged from 0.5mg to 12mg weekly, with the most common being 4mg, 8mg, 9mg and 12mg Different dosing schedules were tested, with most people starting at 2mg and escalating every 4 weeks The 12mg dose produced the most weight loss (up to 28.7% after 68 weeks) Starting at 2mg rather than 4mg helped reduce side effects during escalation First to know Get an email the day retatrutide launches in the UK

Why combine semaglutide and B12

We serve patients from Kingwood TX , Huffman TX, Atascocita TX, Humble TX, Porter TX, New Caney TX, Houston TX, Crosby TX, Dayton TX, Mont Belvieu TX and Spring TX